PURE Insider Trading Activity and SEC Form 4 Filings
PURE insider trading summary
No open-market insider purchases or sales of Pure Bioscience, Inc. (PURE) have been reported on SEC Form 4 in the past 12 months.
Latest PURE insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Mar 22, 2023 | Robert F Bartlett | CEO | Buy | $8K (50,000 @ $0.15) |
| Mar 21, 2023 | Bernard Blotner | Director | Buy | $1K (10,000 @ $0.13) |
| Dec 15, 2022 | Tom Y Lee | Chief Executive Officer | Buy | $7K (50,000 @ $0.13) |
| Mar 21, 2022 | Tom Y Lee | Chief Executive Officer | Buy | $37K (185,000 @ $0.20) |
| Mar 17, 2022 | Tom Y Lee | Chief Executive Officer | Buy | $2K (13,250 @ $0.18) |
| Mar 16, 2022 | Tom Y Lee | Chief Executive Officer | Buy | $4K (21,227 @ $0.18) |
| Jun 16, 2021 | Tom Y Lee | Chief Executive Officer | Buy | $16K (35,998 @ $0.43) |
| Dec 24, 2020 | Tom Y Lee | Chief Executive Officer | Buy | $553 (851 @ $0.65) |
| Dec 22, 2020 | Tom Y Lee | Chief Executive Officer | Buy | $30K (45,299 @ $0.66) |
| Dec 21, 2020 | Tom Y Lee | Chief Executive Officer | Buy | $5K (7,859 @ $0.68) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.